BioSpace News Archive

AGC Biologics announces a change in executive leadership.

Strengthens Leadership Team with Appointment of Douglas Jacobstein, M.D. as V.P. of Clinical Development and Alex Rabiee as V.P. of Business Development

CASI Pharmaceuticals, Inc. announced that Wei-Wu He, Ph.D., Executive Chairman of CASI, has been appointed Chief Executive Officer.

Eight patients treated with SB-525 gene therapy showed dose-dependent increases in FVIII activity, with the two patients treated with the 3e13 vg/kg dose reaching normal FVIII levels

Balanced in-house and contract manufacturing strategy to provide clinical and commercial supply for Sangamo’s growing pipeline of AAV-based genomic therapies

Novocure announced that it will report financial results for the first quarter 2019 on Thursday, May 2, 2019, before the U.S. financial markets open.

Alligator Bioscience, announce that new preclinical data on the drug candidate ATOR-1144 will be presented at the scientific conference AACR, held in Atlanta on March 29 - April 3, 2019.

Dermelix has formed a partnership with EspeRare to develop and commercialize DMX-101 for a rare pediatric disease called XLHED

Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH), parent company of Lantheus Medical Imaging, Inc. (“LMI”), a global leader in the development, manufacture and commercialization of innovative diagnostic imaging agents and products, today announced it has entered into a strategic collaboration with Cerevast Medical, Inc. (“Cerevast”) for the treatment of retinal vein occlusion (RVO), one of the most common causes of vision loss worldwide.

Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer, autoimmune disease, asthma and allergic diseases, today announced it has entered into a research and license agreement in which Astellas Pharma Inc. will access Xencor’s bispecific technology to advance a novel bispecific antibody program in oncology